Medrio, a provider of eClinical technology for pharma, medical device, and diagnostic companies conducting clinical trials, and Bioforum, a data-focused contract research organization (CRO) offering end-to-end services to life sciences companies worldwide, have announced a partnership to optimize the clinical data standardization process. The collaboration will provide Medrio clients with access to JET-Convert, Bioforum’s solution for standardizing clinical data in a regulatory compliant, submission-ready format, furthering efforts to accelerate clinical trial timelines while improving patient safety and outcomes.
Leveraging artificial intelligence (AI) technology, Bioforum’s solution automates clinical data standardization using a submission-ready format that follows Clinical Data Interchange Standards Consortium (CDISC) guidelines. Required by the FDA, CDISC standards address the need to better structure and improve the quality and consistency of research data, allowing for the meaningful exchange of information between all clinical trial stakeholders, including clinicians, researchers, pharmaceutical companies and regulatory authorities.
“Reducing variation and standardizing clinical data is central to improving its quality and usability,” said Mike Novotny, Founder and Chief Executive Officer of Medrio. “We’re thrilled to partner with Bioforum and provide our clients with access to its pioneering JET-Convert solution, a powerful tool that will enable better data integration and reusability, the facilitation of data exchange with partners as well as regulatory reviews and audits, and, ultimately, speed up efforts to bring innovative medical treatments to patients around the world.”
Bioforum’s Co-Founder and President Amir Malka added, “Our partnership with Medrio addresses the industry’s urgent need for a solution that can standardize clinical data at scale. We’re excited to launch this collaboration and confident that together we can help our life sciences clients improve efficiencies in all stages of clinical development-from study design and start-up through execution and submission.”
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.